Kapecytabina (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Kapecytabina" in Polish language version.

refsWebsite

Global rank Polish rank

13nih.gov

4^th place

7^th place

10doi.org

2^nd place

6^th place

2web.archive.org

1^st place

1worldcat.org

5^th place

2^nd place

1drugbank.ca

4,294^th place

205^th place

1termedia.pl

low place

624^th place

1roche.pl

low place

1mp.pl

8,738^th place

165^th place

1ascopubs.org

low place

8,458^th place

1annalsofoncology.org

low place

1gsk.com.pl

low place

annalsofoncology.org

J. Cassidy, L. Saltz, C. Twelves, E. Van Cutsem i inni. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. „Ann Oncol”. 22 (12), s. 2604–2609, grudzień 2011. DOI: 10.1093/annonc/mdr031. PMID: 21415237.

ascopubs.org

jco.ascopubs.org

D.G. Haller, J. Tabernero, J. Maroun, F. de Braud i inni. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. „J Clin Oncol”. 29 (11), s. 1465–1471, kwiecień 2011. DOI: 10.1200/JCO.2010.33.6297. PMID: 21383294.

doi.org

C.J. Twelves. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. „Clin Colorectal Cancer”. 6 (4), s. 278–287, listopad 2006. DOI: 10.3816/CCC.2006.n.046. PMID: 17241512.
D.G. Haller, J. Tabernero, J. Maroun, F. de Braud i inni. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. „J Clin Oncol”. 29 (11), s. 1465–1471, kwiecień 2011. DOI: 10.1200/JCO.2010.33.6297. PMID: 21383294.
J. Cassidy, L. Saltz, C. Twelves, E. Van Cutsem i inni. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. „Ann Oncol”. 22 (12), s. 2604–2609, grudzień 2011. DOI: 10.1093/annonc/mdr031. PMID: 21415237.
J. Cassidy, S. Clarke, E. Díaz-Rubio, W. Scheithauer i inni. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. „J Clin Oncol”. 26 (12), s. 2006–2012, kwiecień 2008. DOI: 10.1200/JCO.2007.14.9898. PMID: 18421053.
M. Koopman, N.F. Antonini, J. Douma, J. Wals i inni. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. „Lancet”. 370 (9582), s. 135–142, lipiec 2007. DOI: 10.1016/S0140-6736(07)61086-1. PMID: 17630036.
F. Montagnani, A. Chiriatti, S. Licitra, C. Aliberti i inni. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. „Clin Colorectal Cancer”. 9 (4), s. 243–247, październik 2010. DOI: 10.3816/CCC.2010.n.036. PMID: 20920997.
W. Schmiegel, A. Reinacher-Schick, D. Arnold, S. Kubicka i inni. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. „Ann Oncol”. 24 (6), s. 1580–1587, czerwiec 2013. DOI: 10.1093/annonc/mdt028. PMID: 23463625.
D. Cunningham, N. Starling, S. Rao, T. Iveson i inni. Capecitabine and oxaliplatin for advanced esophagogastric cancer. „N Engl J Med”. 358 (1), s. 36–46, styczeń 2008. DOI: 10.1056/NEJMoa073149. PMID: 18172173.
Y.K. Kang, W.K. Kang, D.B. Shin, J. Chen i inni. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. „Ann Oncol”. 20 (4), s. 666–673, kwiecień 2009. DOI: 10.1093/annonc/mdn717. PMID: 19153121.
A.F. Okines, A.R. Norman, P. McCloud, Y.K. Kang i inni. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. „Ann Oncol”. 20 (9), s. 1529–1534, wrzesień 2009. DOI: 10.1093/annonc/mdp047. PMID: 19474114.

drugbank.ca

Capecitabine, [w:] DrugBank [online], University of Alberta, DB01101 (ang.).

gsk.com.pl

Binoda charakterystyka produktu leczniczego [online] [dostęp 2015-10-25] [zarchiwizowane z adresu 2016-03-07] .

mp.pl

indeks.mp.pl

Kapecytabina (capecitabine).

nih.gov

ncbi.nlm.nih.gov

C.J. Twelves. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. „Clin Colorectal Cancer”. 6 (4), s. 278–287, listopad 2006. DOI: 10.3816/CCC.2006.n.046. PMID: 17241512.
D.G. Haller, J. Tabernero, J. Maroun, F. de Braud i inni. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. „J Clin Oncol”. 29 (11), s. 1465–1471, kwiecień 2011. DOI: 10.1200/JCO.2010.33.6297. PMID: 21383294.
P.M. Hoff, R. Ansari, G. Batist, J. Cox i inni. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. „J Clin Oncol”. 19 (8), s. 2282–2292, kwiecień 2001. PMID: 11304782.
E. Van Cutsem, C. Twelves, J. Cassidy, D. Allman i inni. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. „J Clin Oncol”. 19 (21), s. 4097–4106, listopad 2001. PMID: 11689577.
J. Cassidy, L. Saltz, C. Twelves, E. Van Cutsem i inni. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. „Ann Oncol”. 22 (12), s. 2604–2609, grudzień 2011. DOI: 10.1093/annonc/mdr031. PMID: 21415237.
J. Cassidy, S. Clarke, E. Díaz-Rubio, W. Scheithauer i inni. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. „J Clin Oncol”. 26 (12), s. 2006–2012, kwiecień 2008. DOI: 10.1200/JCO.2007.14.9898. PMID: 18421053.
M. Koopman, N.F. Antonini, J. Douma, J. Wals i inni. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. „Lancet”. 370 (9582), s. 135–142, lipiec 2007. DOI: 10.1016/S0140-6736(07)61086-1. PMID: 17630036.
F. Montagnani, A. Chiriatti, S. Licitra, C. Aliberti i inni. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. „Clin Colorectal Cancer”. 9 (4), s. 243–247, październik 2010. DOI: 10.3816/CCC.2010.n.036. PMID: 20920997.
W. Schmiegel, A. Reinacher-Schick, D. Arnold, S. Kubicka i inni. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. „Ann Oncol”. 24 (6), s. 1580–1587, czerwiec 2013. DOI: 10.1093/annonc/mdt028. PMID: 23463625.
D. Cunningham, N. Starling, S. Rao, T. Iveson i inni. Capecitabine and oxaliplatin for advanced esophagogastric cancer. „N Engl J Med”. 358 (1), s. 36–46, styczeń 2008. DOI: 10.1056/NEJMoa073149. PMID: 18172173.
Y.K. Kang, W.K. Kang, D.B. Shin, J. Chen i inni. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. „Ann Oncol”. 20 (4), s. 666–673, kwiecień 2009. DOI: 10.1093/annonc/mdn717. PMID: 19153121.
A.F. Okines, A.R. Norman, P. McCloud, Y.K. Kang i inni. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. „Ann Oncol”. 20 (9), s. 1529–1534, wrzesień 2009. DOI: 10.1093/annonc/mdp047. PMID: 19474114.
J. O’Shaughnessy, D. Miles, S. Vukelja, V. Moiseyenko i inni. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. „J Clin Oncol”. 20 (12), s. 2812–2823, czerwiec 2002. PMID: 12065558.

roche.pl

Xeloda charakterystyka produktu leczniczego [online] [dostęp 2016-05-11] [zarchiwizowane z adresu 2016-04-09] .

termedia.pl

Rafał Stec, Lubomir Bodnar, Cezary Szczylik. Capecitabine in palliative chemotherapy of colorectal cancer – efficacy and toxicity. „Współczesna Onkologia”, 2009.

web.archive.org

Xeloda charakterystyka produktu leczniczego [online] [dostęp 2016-05-11] [zarchiwizowane z adresu 2016-04-09] .
Binoda charakterystyka produktu leczniczego [online] [dostęp 2015-10-25] [zarchiwizowane z adresu 2016-03-07] .

worldcat.org

Capecitabine, [w:] Merck Index. An Encyclopedia of Chemicals, Drugs, and Biologicals, wyd. 14, Whitehouse Station, New Jersey: Merck & Company, 2006, ISBN 978-0-911910-00-1, OCLC 938242785 (ang.).